Under the new FDA leadership, COVID vaccine makers are seeing greater regulatory scrutiny and facing tighter requirements for their shots that could increase their expenses. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/moderna-seeks-fda-approval-for-updated-covid-vaccine-targeting-dominant-strain/121372219